Literature DB >> 15858959

Effects of Saccharomyces boulardii in children with acute diarrhoea.

Z Kurugöl1, G Koturoğlu.   

Abstract

AIM: Certain probiotic agents, e.g. Lactobacillus GG, have shown efficacy in clinical trials for the treatment of acute childhood diarrhoea, but few studies have examined the effect of Saccharomyces boulardii. We evaluated the effect of S. boulardii in children with acute diarrhoea.
METHODS: Two hundred children were randomized to receive S. boulardii in a granulated form in a daily dose of 250 mg (S. boulardii group) or placebo (placebo group) for 5 d. Clinical and demographic characteristics on admission were similar between the study groups.
RESULTS: The medians of the average stool frequency after the second day of the treatment were significantly lower in the S. boulardii group than in the placebo group (p = 0.003). The duration of diarrhoea significantly reduced in the S. boulardii group compared with the placebo group (4.7 vs 5.5 d, p = 0.03). The effect of S. boulardii on watery diarrhoea became apparent after the second day of the treatment. The duration of hospital stay was shorter in the S. boulardii group than in the placebo group (2.9 vs 3.9 d, p < 0.001). Four children from the placebo group versus only one child from the S. boulardii group had persisting diarrhoea.
CONCLUSION: The placebo-controlled study suggested that S. boulardii significantly reduced the duration of acute diarrhoea and the duration of hospital stay. S. boulardii seems to be a promising agent for the amelioration of the course of acute diarrhoea in children when used therapeutically.

Entities:  

Mesh:

Year:  2005        PMID: 15858959     DOI: 10.1111/j.1651-2227.2005.tb01786.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  31 in total

1.  Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection.

Authors:  Ener Cagri Dinleyici; Makbule Eren; Nihal Dogan; Serap Reyhanioglu; Zeynel Abidin Yargic; Yvan Vandenplas
Journal:  Parasitol Res       Date:  2010-10-05       Impact factor: 2.289

2.  The effect of a multi-strain probiotic on the resistance toward Escherichia coli challenge in a randomized, placebo-controlled, double-blind intervention study.

Authors:  S J M Ten Bruggencate; S A Girard; E G M Floris-Vollenbroek; R Bhardwaj; T A Tompkins
Journal:  Eur J Clin Nutr       Date:  2014-11-05       Impact factor: 4.016

Review 3.  Probiotics, enteric and diarrheal diseases, and global health.

Authors:  Geoffrey A Preidis; Colin Hill; Richard L Guerrant; B S Ramakrishna; Gerald W Tannock; James Versalovic
Journal:  Gastroenterology       Date:  2010-11-12       Impact factor: 22.682

Review 4.  Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspectives.

Authors:  Jean-Paul Buts
Journal:  Dig Dis Sci       Date:  2008-06-05       Impact factor: 3.199

5.  Probiotics to prevent the need for, and augment the use of, antibiotics.

Authors:  Gregor Reid
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-09       Impact factor: 2.471

6.  Proinflammatory and anti-inflammatory cytokines present in the acute phase of experimental colitis treated with Saccharomyces boulardii.

Authors:  Nathália Nahas Grijó; Ricardo Carneiro Borra; Vera Lucia Sdepanian
Journal:  Dig Dis Sci       Date:  2009-12-09       Impact factor: 3.199

7.  Clinical efficacy comparison of Saccharomyces boulardii and yogurt fluid in acute non-bloody diarrhea in children: a randomized, controlled, open label study.

Authors:  Makbule Eren; Ener C Dinleyici; Yvan Vandenplas
Journal:  Am J Trop Med Hyg       Date:  2010-03       Impact factor: 2.345

Review 8.  Some current applications, limitations and future perspectives of lactic acid bacteria as probiotics.

Authors:  Smith Etareri Evivie; Gui-Cheng Huo; John Oamen Igene; Xin Bian
Journal:  Food Nutr Res       Date:  2017-05-03       Impact factor: 3.894

9.  Immunological and central nervous system changes in mice suffering from Staphyloccocus aureus and treated with Saccharomyces cerevisiae var. vini living cells.

Authors:  I Ochigava; L Kalandarishvili; M Zhvania
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.099

Review 10.  Saccharomyces boulardii in childhood.

Authors:  Yvan Vandenplas; Oscar Brunser; Hania Szajewska
Journal:  Eur J Pediatr       Date:  2008-12-19       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.